Research article · 10 Apr 2025
Conference abstractPublished 20 Oct 2014
Using small molecule estrogen receptor biomodulators to identify new pathways and as anticancer drugs
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Estrogens, acting via estrogen receptor (ER), stimulate cell proliferation, and tumor growth. Endocrine therapy targeting these tumors using aromatase inhibitors to inhibit estrogen production, and tamoxifen and other antiestrogens that compete with estrogens for binding to ER, is a mainstay in breast cancer treatment. Selection and outgrowth of resistant tumors is common. Screening identified a lead non-competitive ER inhibitor. At sub-micromolar concentrations, the inhibitor blocked proliferation of ER positive breast, ovarian and endometrial cancer cells-including cells resistant to tamoxifen and Fulvestrant/Faslodex/ICI 182,780. The compound had no effect in ER negative cells. In a mouse xenograft model, the inhibitor was not toxic and induced rapid and substantial tumor regression. This unusual ER inhibitor is so effective because it targets multiple pathways. Independent of its other effects, the compound rapidly inhibits estrogen-ER induction and repression of gene expression. Chromatin immunoprepcipitation (ChIP) shows the compound inhibits recruitment of ER to regulatory regions of estrogen responsive genes. The compound also acts outside the cell nucleus to regulate pathways not previously linked to ER action. Subsequent investigation revealed that the inhibitor distorts and amplifies a previously undesribed action of estrogen and ER, leading to death of the ER containing cancer cells. Our studies demonstrate the potential of targeted cellbased screening to reveal new pathways of action, coregulators and small molecule therapeutic candidates; even in a system as intensively studied as ER positive cancer. Supported by NIH DK-017909.
Subjects
Diabetes & EndocrinologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Endocrinology & Metabolic Syndrome.
Perspective · 22 Jan 2025
Stem Cells of Endocrine Organs in Normal Physiology and Disease
Perspective · 20 Jan 2025
An In-Depth Overview of Reproductive Endocrinology
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalEndocrinology & Metabolic Syndrome
- SubjectDiabetes & Endocrinology
- BylineArticles whose byline prints “David J Shapiro”
